Nitrofurantoin Potential for pulmonary and hepatic toxicity, peripheral neuropathy esp with long term use Avoid if CrCl <30 or for long term suppression 2019 AGS Beers Criteria Update NCQA Medicare Advisory Panel HEDIS High Risk Medications (HRMs) Payer adoption of HRMs Pharmacy Benefits Manager PA
2 The chart below summarizes the 2019 Beers list, potential therapeutic alternatives, and other considerations
First developed in 1991 by Dr
Pharmacy Quality Alliance (PQA): Nitrofurantoin (when cumulative day supply is greater than 90 days) is identified as a high-risk medication in patients 65 years and older on the PQA's Use of High-Risk Nitrofurantoin is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to its potential for pulmonary toxicity, hepatotoxicity, and peripheral neuropathy, particularly when given long-term
Concurrent drug therapy issues: [IDSA 2019])
The Beers Criteria is a tool designed to alert health-care providers to the potential
In E
0%, According to the American Geriatrics Society Beers Criteria Update of 2012, using NF for a long time in elderly patients with renal failure must be banned